Search Videos and More
Video
Matthew Davids, MD, MMSc discusses time-limited AVO triplet therapy
In a new study published in the Journal of Clinical Oncology and presented at #ASH24, Matthew Davids, MD, MMSC, of Dana-Farber Cancer Institute, shared promising findings: a time-limited AVO triplet therapy offers durable remission for high-risk CLL patients.
Video
Jennifer Brown, MD, PhD reviews Phase 2 Amplify trial
Dana-Farber Cancer Institute's Jennifer Brown, MD, PhD, shared results at #ASH24 from the Phase 3 AMPLIFY trial: novel oral regimens show promise for CLL with durable, deep responses.
Video
Jacqueline Garcia, MD on oral maintenance therapy in AML/MDS patients
Jacqueline Garcia, MD, of Dana-Farber Cancer Institute presented at #ASH24 data suggesting oral maintenance therapy with venetoclax and decitabine/cedazuridine after HCT is safe, feasible, and may reduce relapse rates in high-risk AML/MDS patients.
Video
Shai Shimony, MD, MPH reviews Phase 3 acute myeloid leukemia trial
Findings from a Phase 3 acute myeloid leukemia trial presented at #ASH24 show CPX-351 improves survival for AML-MR patients. Lead authors Shai Shimony, MD, MPH, and H. Moses Murdoch, MD, of Dana-Farber Cancer Institute, explain more in this video.
Video
Katie Maurer, MD, PhD discusses HSCT treatment
Katie Maurer, MD, PhD, from Dana-Farber Cancer Institute, shared #ASH24 findings suggesting that diverse bone marrow cell composition may predict treatment response in the content of AML patients undergoing HSCT.
News
Study Finds Care After Donor Stem Cell Transplant Can Be Safely Shared Between Transplant Centers and Local Oncologists
Patients undergoing a donor stem-cell transplant for leukemia or other blood-related cancer require months of specialized follow-up care, traditionally delivered at the center where they received their transplant – often a serious challenge for those who live far away.
News
New Research Shows Inherited Genetic Variants Increase Risk of Certain Pediatric Cancers
New research from Dana-Farber Cancer Institute has found that rare germline genetic abnormalities could increase the risk of childhood cancers such as neuroblastoma, Ewing sarcoma, and osteosarcoma.
News
Dana-Farber Research News 01.01.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from December 1 through December 15.
News
Turning Up the Heat: Dana-Farber Scientists Describe Key Molecular Shift in Brown Fat Cells
Brown fat is a specialized tissue that has developed a host of important functions over the course of evolution. One of the most critical: the ability to produce heat in response to low temperatures by burning energy.
Video
Ann Partridge, MD, MPH Presents PROs from the COMET Study
Patients with low-risk DCIS who underwent active monitoring had comparable physical, emotional, and psychological outcomes to patients who received standard treatment, according to results from the phase 3 COMET trial data.
Video
Judy Garber, MD, MPH Presents Updated Results of the OlympiA Study
Dana-Farber’s Judy Garber, MD, MPH shared updated results from the phase 3 OlympiA study. The new analysis provides further support for olaparib’s benefits in patients with high-risk, HER2-negative breast cancer with germline mutations in BRCA1 or BRCA2.
Video
Ada Waks, MD Presents Results of the MARGOT Study
Dana-Farber's Ada Waks, MD presented results of MARGOT, a phase 2 trial comparing margetuximab plus chemo or trastuzumab plus chemo in patients with early stage HER2+ breast cancer.